Greenlab partners with Canada’s Purplefarm Genetics to develop unique cannabinoids for the medical market.
New Zealand-based biotech company Greenlab has signed an agreement with private Canadian cannabis company Purplefarm Genetics to develop next-generation medicinal cannabis strains.
Founded in 2019, Greenlab was one of the first companies in New Zealand’s South Island to receive a license for research and development in the field of cannabis. The laboratory is located at Lincoln University near Christchurch.
Purplefarm is also licensed to grow, process and sell cannabis for medicinal purposes at its facility in Johnstown, Ontario, Canada. The company is an experienced grower of whole flower cannabis for the Canadian and global markets.
The two companies have been operating since 2020.
Pushing the boundaries of therapeutic cannabinoids
Jonah Clifford, director of Purplefarm Genetics, said the couple share a common goal of producing high levels of unique cannabinoids, terpenes and flavonoids that “bring great value to patients, consumers and our businesses.”
“Greenlab’s leadership in medical cannabis germplasm research and development and Purplefarm’s world-class cultivation practices partnership are leveraging our core competencies to create an unprecedented gold standard for cannabis cultivation and compliant product development,” he said.
The new strains will be developed in accordance with the import and export regulations of Health Canada and the New Zealand Department of Health.
Dr. Parmjit Randhawa, director of research and commercialization at Greenlab, added that both companies are driven by a shared passion to push the boundaries of square meter yields of therapeutic cannabinoids to result in “unique pharmaceutical products that are urgently demanded by physicians and doctors need immunocompromised patients ”.
“The Purplefarm Genetics team has a wealth of cultivation skills, an extensive Canadian strain library, and a precision-engineered facility that complements the fully controlled Greenlab environmental research at Lincoln University to quickly track product development efforts,” said Dr. Randhawa.
Australian supply contract
Earlier this year, Greenlab’s Australian subsidiary signed a two-year contract to supply pharmaceutical grade cannabinoid products to Australian medical cannabis distributor Cannvalate for sale to approved patients.